Citations

Clear

4847 citation(s) found for "Yu, Eric".

Common Language Description of the Term Rheumatic and Musculoskeletal Diseases (RMDs) for Use in Communication With the Lay Public, Healthcare Providers, and Other Stakeholders Endorsed by the European League Against Rheumatism (EULAR
Daikh, David, Betteridge, Neil , Burmester, Gerd R , Hassett, Afton L. , Matteson, Eric L. , Vollenhoven, Ronald van , Lakhanpal, Sharad, Heijde, Désirée M F M van der , Burmester, Gerd-Rüdiger

Mayo Clinic

Arthritis & Rheumatology | March 15, 2018 | Volume: 70 | Issue: 6 | Pages: 826-831

10.1002/art.40448 | PMID 29532625 Get It

A European League Against Rheumatism–American College of Rheumatology working group consisting of practicing and academic rheumatologists, a rheumatology researcher, and a patient representative created a succinct general statement describing rheumatic and musculoskeletal diseases (RMDs) in adults and children in language that can be used in conversations with the lay public, media, healthcare providers, and other stakeholders. Based on the literature review, several elements were deemed important for inclusion in the description of RMDs. First, RMDs encompass many different diseases that can affect individuals at any age, including children. Second, there are various pathophysiological pathways underlying different RMDs. Third, the impact of RMDs on individuals and society should be emphasized. The working group agreed that the language should be comprehensible to the lay public. Thus, the following description of RMDs has been developed: “Rheumatic and musculoskeletal diseases (RMDs) are a diverse group of diseases that commonly affect the joints, but can affect any organ of the body. There are more than 200 different RMDs, affecting both children and adults. They are usually caused by problems of the immune system, inflammation, infections, or gradual deterioration of joints, muscles, and bones. Many of these diseases are long term and worsen over time. They are typically painful and limit function. In severe cases, RMDs can result in significant disability, having a major impact on both quality of life and life expectancy.” This description can be used by rheumatology groups, researchers, and those who work in advocacy and education related to RMDs.
Genome Wide Association Study Identifies the HMGCS2 Locus to be Associated With Chlorthalidone Induced Glucose Increase in Hypertensive Patients
McDonough, Caitrin W. , Alghamdi, Wael A. , Arwood, Meghan J. , Bargal, Salma A. , Dumeny, Leanne , Mehanna, Mai , Stockard, Bradley , Yang, Guang , Oliveira, Felipe A. de, Fredette, Natalie C., Shahin, Mohamed H. , Bailey, Kent R. , Beitelshees, Amber L. , Boerwinkle, Eric , Chapman, Arlene B. , Gums, John G. , Johnson, Julie A. , Beitelshees, Amber L. , Turner, Stephen T. , Singh, Sonal , Gong, Yan , Li, Wenyi , Chapman, Arlene B. , Cooper‐DeHoff, Rhonda M.

Mayo Clinic

Journal of the American Heart Association | March 10, 2018 | Volume: 7 | Issue: 6 | Pages: No page available

10.1161/jaha.117.007339 | PMID 29523524 Get It

Background Thiazide and thiazide‐like diuretics are first‐line medications for treating uncomplicated hypertension. However, their use has been associated with adverse metabolic events, including hyperglycemia and incident diabetes mellitus, with incompletely understood mechanisms. Our goal was to identify genomic variants associated with thiazide‐like diuretic/chlorthalidone‐induced glucose change. Methods and Results Genome‐wide analysis of glucose change after treatment with chlorthalidone was performed by race among the white (n=175) and black (n=135) participants from the PEAR ‐2 (Pharmacogenomic Evaluation of Antihypertensive Responses‐2). Single‐nucleotide polymorphisms with P <5×10 −8 were further prioritized using in silico analysis based on their expression quantitative trait loci function. Among blacks, an intronic single‐nucleotide polymorphism (rs9943291) in the HMGCS 2 was associated with increase in glucose levels following chlorthalidone treatment (ß=12.5; P =4.17×10 −8 ). G‐allele carriers of HMGCS 2 had higher glucose levels (glucose change=+16.29 mg/dL) post chlorthalidone treatment compared with noncarriers of G allele (glucose change=+2.80 mg/dL). This association was successfully replicated in an independent replication cohort of hydrochlorothiazide‐treated participants from the PEAR study (ß=5.54; P =0.023). A meta‐analysis of the 2 studies was performed by race in Meta‐Analysis Helper, where this single‐nucleotide polymorphism, rs9943291, was genome‐wide significant with a meta‐analysis P value of 3.71×10 −8 . HMGCS 2 , a part of the HMG ‐CoA synthase family, is important for ketogenesis and cholesterol synthesis pathways that are essential in glucose homeostasis. Conclusions These results suggest that HMGCS 2 is a promising candidate gene involved in chlorthalidone and Hydrochlorothiazide (HCTZ)‐induced glucose change. This may provide insights into the mechanisms involved in thiazide‐induced hyperglycemia that may ultimately facilitate personalized approaches to antihypertensive selection for hypertension treatment. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifiers: NCT 00246519 and NCT 01203852.
I Am What I Am Because of Who We All Are
Braman, Jonathan P. , Freedman, Brett A. , Gofton, Wade , Hsu, Joseph R. , Sheps, David S., Strauss, Eric J. , Bernthal, Nicholas M

Mayo Clinic

Journal of Bone and Joint Surgery | March 7, 2018 | Volume: 100 | Issue: 5 | Pages: e28

10.2106/jbjs.17.00812 | PMID 29509624 Get It

VEGF-mediated angiogenesis and vascularization of a fumarate-crosslinked polycaprolactone (PCLF) scaffold
Wagner, Eric R. , Parry, Joshua A. , Dadsetan, Mahrokh, Bravo, Dalibel , Riester, Scott M. , Wijnen, André J. van , Yaszemski, Michael J. , Parry, Joshua, van Wijnen, Andre J , Wagner, Eric R , Kakar, Sanjeev

Mayo Clinic

Connective Tissue Research | March 7, 2018 | Volume: 59 | Issue: 6 | Pages: 542-549

10.1080/03008207.2018.1424145 | PMID 29513041 Get It

Buying Time: Long-Term Results of Wrist Denervation and Time to Repeat Surgery
O’Shaughnessy, Maureen , Wagner, Eric R. , Berger, Richard A. , O'Shaughnessy, Maureen A, Wagner, Eric R , Kakar, Sanjeev

Mayo Clinic

HAND | March 5, 2018 | Volume: 14 | Issue: 5 | Pages: 602-608

10.1177/1558944718760031 | PMID 29504473 Get It

Background: This study reviews long-term outcomes of partial wrist denervation focusing on need for and time to revision procedure. Methods: A retrospective study was conducted of all patients undergoing partial wrist denervation between 1994 and 2014. At average latest follow-up of 6.75 years (range, 1-21 years), clinical and radiographic data and need for revision surgery were recorded. Results: There were 100 wrists in 89 patients (61 male, 28 female) with average age at surgery of 54 years (range, 26-80). Principal diagnoses were arthritis (58%), inflammatory (19%), and posttraumatic arthritis (7%). Average flexion-extension arc was 83% and grip strength 75% of unaffected extremity. Average Mayo Wrist Scores improved from 48 preoperatively to 77 postoperatively. Sixty-nine percent of patients did not undergo other procedures during the time interval studied. Thirty-one percent underwent revision at an average of 26 months following denervation (range, 2-165). Conclusions: Partial wrist denervation is a motion-preserving procedure for patients with refractory wrist pain with 69% in this series requiring no further procedures. The remaining 31% experienced average symptom relief for 2 years prior to ultimately undergoing revision operation.
Arthroscopic Latarjet Procedure Combined With Bankart Repair: A Technique Using 2 Cortical Buttons and Specific Glenoid and Coracoid Guides
Valenti, Philippe , Maroun, Charbel , Wagner, Eric R. , Werthel, Jean-David , Wagner, Eric, Wagner, Eric R

Mayo Clinic

Arthroscopy Techniques | March 5, 2018 | Volume: 7 | Issue: 4 | Pages: No page available

10.1016/j.eats.2017.09.009 | PMID 29868397 Get It

Abstract The arthroscopic Latarjet procedure is challenging because it can be difficult to place 2 screws parallel to the glenoid surface and a medial portal (dangerous for the brachial plexus) is mandatory. In addition, precise positioning of the coracoid bone block flush with the joint line and in a subequatorial position as recommended is troublesome without the use of a guiding system because of the arthroscopic lens distortion. To improve the reproducibility of the arthroscopic Latarjet procedure and to minimize the risk of nerve complications, we developed a guiding system to optimize the positioning of the coracoid bone block and 2 cortical buttons to facilitate its fixation. Four portals are used: a posterior standard portal and 3 anterior portals, all lateral to the conjoint tendon. The anterior rim of the glenoid and the coracoid process are prepared. Two holes are drilled in the glenoid and in the coracoid process with 2 specific guides. The subscapularis is then split, and 2 cortical buttons are passed from posterior to anterior through the tunnels with a shuttle relay. The coracoid process undergoes osteotomy and is guided through the split in the subscapularis to the anteroinferior rim of the glenoid by pulling on the cortical buttons. Technique Video video See video under supplementary data.
Hospitalisation rates among patients with primary Sjögren’s syndrome: a population-based study, 1995–2016
Maciel, Gabriel, Servioli, Luisa, Nannini, Carlotta, Berti, Alvise , Crowson, Cynthia S. , Achenbach, Sara J., Matteson, Eric L. , Cornec, Divi, Berti, Alvise , Cornec, Divi

Mayo Clinic

RMD Open | February 28, 2018 | Volume: 4 | Issue: 1 | Pages: e000575

10.1136/rmdopen-2017-000575 | PMID 29531781 Get It

Objective To determine rates and primary discharge diagnoses of hospitalisation in a cohort of patients with incident primary Sjögren’s syndrome (pSS) compared with the general population. Methods This was a retrospective population-based cohort study focused on Olmsted County, Minnesota. The pSS cohort consisted of patients with incident pSS in the 1976–2015 period and was compared with a cohort of individuals without pSS matched 3:1 for age, sex and calendar year, randomly selected from the same population. Hospitalisations in 1995–2016 were examined. Discharge diagnoses were categorised using the Clinical Classifications Software for International Classification of Diseases, 9th revision, Clinical Modification. Results A total of 385 hospitalisations occurred in the 160 patients with pSS during 1592 person-years of follow-up. Among 466 comparators, there were 899 hospitalisations during 4660 person-years of follow-up, resulting in a significantly higher rate of hospitalisations in patients with pSS (rate ratio (RR): 1.25, 95% CI: 1.11 to 1.41). Rates of hospitalisation were increased among patients with pSS for endocrine, nutritional and metabolic diseases and immunity disorders (RR 1.82, 95% CI 1.08 to 2.98), diseases of the musculoskeletal system and connective tissue (RR 1.49, 95% CI 1.05 to 2.05) and for injuries and poisoning (RR 1.46, 95% CI 1.01 to 2.06). While not significantly increased overall, hospitalisations for diseases of the circulatory system were significantly increased in patients with pSS aged ≥75 years (RR 1.54, 95% CI 1.11 to 2.11). Conclusions Patients with pSS experienced higher rates of hospitalisation than the general population. Hospitalisations for endocrine/metabolic disorders, diseases of the circulatory system, diseases of the musculoskeletal system and connective tissue disorders, and injuries were more common among patients with pSS than comparators.
Time‐resolved contrast‐enhanced MR angiography with single‐echo Dixon fat suppression
Stinson, Eric G. , Trzasko, Joshua D. , Glockner, James F., Young, Phillip M. , Riederer, Stephen J. , Campeau, Norbert G. , Huston, John

Mayo Clinic

Magnetic Resonance in Medicine | February 28, 2018 | Volume: 80 | Issue: 4 | Pages: 1556-1567

10.1002/mrm.27152 | PMID 29488251 Get It

PurposeDixon‐based fat suppression has recently gained interest for dynamic contrast‐enhanced MRI, but multi‐echo techniques require longer scan times and reduce temporal resolution compared to single‐echo alternatives without fat suppression. The purpose of this work is to demonstrate accelerated single‐echo Dixon imaging with high spatial and temporal resolution.Theory and MethodsReal‐valued water and fat images can be obtained from a single measurement if the shared initial phase and that due to are assumed known a priori. An expression for simultaneous sensitivity encoding (SENSE) unfolding and fat‐water separation is derived for the general undersampling case, and simplified under the special case of uniform Cartesian undersampling. In vivo experiments were performed in extremities and brain with SENSE acceleration factors of up to R = 8.ResultsSingle‐echo Dixon reconstruction of highly undersampled data was successfully demonstrated. Dynamic contrast‐enhanced water and fat images provided high spatial and temporal resolution dynamic images with image update times shorter than previous single‐echo Dixon work.ConclusionTime‐resolved contrast‐enhanced MRI with single‐echo Dixon fat suppression shows high image quality, improved vessel delineation, and reduced sensitivity to motion when compared to time‐subtraction methods.
Prognostic impact of DNA repair germline variants in hormone sensitive prostate cancer stage.
Lilyquist, Jenna , Kohli, Manish , Hart, Steven N. , Hu, Chunling , Hillman, David W. , Lee, Kun Hee , Gnanaolivu, Rohan , Polley, Eric C. , Couch, Fergus J.

Mayo Clinic

Journal of Clinical Oncology | February 26, 2018 | Volume: 36 | Issue: 6_suppl | Pages: 262-262

10.1200/jco.2018.36.6_suppl.262 Get It

262 Background: Inherited and somatic aberrations in DNA repair genes in castrate resistant prostate cancer (CRPC) are associated with poor prognosis, but respond well to poly ADP ribose polymerase (PARP) inhibitors. We evaluated the prevalence and prognostic impact of harboring germline DNA repair variants in hormone sensitive prostate cancer (HSPC). Methods: Germline DNA from buffy coat was sequenced on HiSeq4000 with a median coverage of 200X for DNA repair variants in 20 genes in HSPC and CRPC patients (pts) enrolled in a hospital registry. Pts were divided into two groups; Group A: pts enrolled at the time of CRPC stage; Group B: treatment naïve HSPC stage pts. The primary endpoints were to determine any impact of harboring DNA repair variants on time to progression from HSPC to CRPC and, from CRPC to death. Group A pts were retrospectively analyzed for time to progression from HSPC to CRPC while Group B patients were followed prospectively for outcomes. Statistical analysis included Cox proportional hazard models and Wilcoxon Rank sum test with significance at p≤0.05. Results: In Group A, 51/562 CRPC pts (9.07%) had variants in the 20 genes (most frequently in BRCA2; n = 15). 44/51 pts with variants and 399/511 without variants had died. Median time of progression from HSPC to CRPC with/without variants was 22.1 vs. 25.1 months (mths); p-value = 0.679. Median time from CRPC to death with/without variants was 32.2 Vs. 27.7 mths (p = 0.6). In HSPC Group B, 14/100 pts were identified with germline variants in ATM (n = 5), CHEK2 (n = 3), BRCA1 (n = 2), BRCA2 (n = 2), RAD50 (n = 1), and MSH2 (n = 1). 31/100 have died and median time to progression from HSPC to CRPC with/without variants was 15.6 vs.11.8 mths, p-value = 0.76. Conclusions: Pts with germline DNA repair variants detected in HSPC stage were not associated with poor prognosis. Presence of additional somatic DNA repair gene aberrations in cell-free DNA, not investigated in this cohort may add to the prevalence of DNA repair gene variations in HSPC and together impact prognosis adversely so as to provide a rationale for PARP inhibitor therapy in select HSPC stage pts.
Genome‐Wide Association Approach Identified Novel Genetic Predictors of Heart Rate Response to β‐Blockers
Shahin, Mohamed H. , Conrado, Daniela J., González, Daniel , Lobmeyer, Maximilian T. , Beitelshees, Amber L. , Boerwinkle, Eric , Gums, John G. , Chapman, Arlene B. , Johnson, Julie A. , Beitelshees, Amber L. , Turner, Stephen T. , Gong, Yan , Cooper‐DeHoff, Rhonda M.

Mayo Clinic

Journal of the American Heart Association | February 24, 2018 | Volume: 7 | Issue: 5 | Pages: No page available

10.1161/jaha.117.006463 | PMID 29478026 Get It

Background For many indications, the negative chronotropic effect of β‐blockers is important to their efficacy, yet the heart rate ( HR ) response to β‐blockers varies. Herein, we sought to use a genome‐wide association approach to identify novel single nucleotide polymorphisms ( SNP s) associated with HR response to β‐blockers. Methods and Results We first performed 4 genome‐wide association analyses for HR response to atenolol (a β1‐adrenergic receptor blocker) as: (1) monotherapy or (2) add‐on therapy, in 426 whites and 273 blacks separately from the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) study. A meta‐analysis was then performed between the genome‐wide association analysis performed in PEAR atenolol monotherapy and add‐on therapy, in each race separately, using the inverse variance method assuming fixed effects. From this analysis, SNP s associated with HR response to atenolol at a P <1E‐05 were tested for replication in whites (n=200) and blacks (n=168) treated with metoprolol (a β1‐adrenergic receptor blocker). From the genome‐wide association meta‐analyses, SNP rs17117817 near olfactory receptor family10 subfamily‐p‐member1 ( OR 10P1 ), and SNP rs2364349 in sorting nexin‐9 ( SNX 9 ) replicated in blacks. The combined studies meta‐analysis P values for the rs17117817 and rs2364349 reached genome‐wide significance (rs17117817G‐allele; Meta‐β=5.53 beats per minute, Meta‐ P =2E‐09 and rs2364349 A‐allele; Meta‐β=3.5 beats per minute, Meta‐ P =1E‐08). Additionally, SNP s in the OR 10P1 and SNX 9 gene regions were also associated with HR response in whites. Conclusions This study highlights OR 10P1 and SNX 9 as novel genes associated with changes in HR in response to β‐blockers. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifier: NCT 00246519.